Date Filed | Type | Description |
06/30/2023 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.
Txns:
| Granted 1,950,000 options to buy
@ $0.3, valued at
$585k
|
|
06/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/09/2021 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $6.8, valued at
$272k
|
|
06/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/23/2020 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on Magenta Therapeutics, Inc.
Txns:
| Granted 36,377 options to buy
@ $7.85, valued at
$285.6k
|
|
12/23/2020 |
3
| Lawton Alison Frances (Director) has filed a Form 3 on Magenta Therapeutics, Inc. |
12/17/2020 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.
Txns:
| Granted 47,200 options to buy
@ $9.09, valued at
$429k
|
|
12/17/2020 |
3
| Lawton Alison Frances (Director) has filed a Form 3 on Aeglea BioTherapeutics, Inc. |
10/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/06/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/17/2020 |
4
| Lawton Alison Frances (See Remarks) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns:
| Granted 118,500 options to buy
@ $6, valued at
$711k
|
|
03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/18/2019 |
4
| Lawton Alison Frances (See Remarks) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns:
| Granted 150,000 options to buy
@ $6.56, valued at
$984k
|
|
06/25/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/04/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/27/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
06/15/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
03/01/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/04/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/16/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
05/12/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
03/15/2016 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on CoLucid Pharmaceuticals, Inc.
Txns:
| Granted 1,420 options to buy
@ $6.54, valued at
$9.3k
|
|
03/15/2016 |
3
| Lawton Alison Frances (Director) has filed a Form 3 on CoLucid Pharmaceuticals, Inc. |
06/11/2013 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on CUBIST PHARMACEUTICALS INC
Txns:
| Exercised 1,347 restricted stock units
@ $0 |
|
06/11/2013 |
4
| Lawton Alison Frances (COO) has filed a Form 4 on OvaScience, Inc. |
06/06/2013 |
4
| LAWTON ALISON FRANCIS (Director) has filed a Form 4 on Verastem, Inc.
Txns:
| Granted 12,500 options to buy
@ $9.34, valued at
$116.8k
Granted 6,507 options to buy
@ $9.34, valued at
$60.8k
|
|
03/11/2013 |
4
| LAWTON ALISON FRANCIS (COO) has filed a Form 4 on OvaScience, Inc. |
11/27/2012 |
4
| LAWTON ALISON FRANCIS (Director) has filed a Form 4 on Verastem, Inc.
Txns:
| Granted 25,000 options to buy
@ $6.47, valued at
$161.8k
|
|
11/27/2012 |
3
| LAWTON ALISON FRANCIS (Director) has filed a Form 3 on Verastem, Inc. |
06/11/2012 |
4
| LAWTON ALISON FRANCIS (Director) has filed a Form 4 on CUBIST PHARMACEUTICALS INC
Txns:
| Granted 372 shares
@ $0 Granted 9,367 options to buy
@ $41.2, valued at
$385.9k
Granted 1,347 restricted stock units
@ $0 |
|
02/17/2012 |
4
| LAWTON ALISON FRANCIS (Director) has filed a Form 4 on CUBIST PHARMACEUTICALS INC
Txns:
| Granted 10,842 options to buy
@ $40.59, valued at
$440.1k
|
|